EQRx founder Alexis Borisy (Han jingyu/Imaginechina via AP Images)
May 8, 2023 04:01 PM EDTUpdated 05:11 PM
R&D
Pharma

Up­dat­ed: EQRx aban­dons its mis­sion of drug price re­form, will cut more than half of em­ploy­ees

Max Gelman

Senior Editor

EQRx’s plan to up­end the US drug price sys­tem with low­er-cost treat­ments is over.

On Mon­day, it an­nounced a mas­sive strate­gic re­set, slash­ing its pipeline …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

FDA ap­proves Hu­ma­cyte’s lab-grown blood ves­sels in mile­stone for re­gen­er­a­tive med­i­cine

Ex­clu­sive: Flori­da can­cer biotech rais­es $100M Se­ries A

Ac­cel­er­at­ed ap­proval brings Pfiz­er's BRAF in­hibitor to first-line pa­tients

Califf, on his way out at FDA, pre­dicts agency tug-of-war be­tween Ra­maswamy and RFK Jr.

A service from the Financial Times